Medical technology firm Zynex Inc. (ZYXI:NASDAQ), which manufactures and markets non-invasive medical devices for cardiac monitoring, neurological diagnostics, pain management and stroke rehabilitation, yesterday announced "orders and an increased Adjusted EBITDA estimate for Q2/21."
Zynex's CEO Thomas Sandgaard led off by stating, "Our order growth in Q2/21 remained strong at 247% year-over-year and 186% for H1/21."
Sandgaard continued, "The company is confirming its previous revenue estimate for Q2/21 of between $31.0-32.5 million. Q2/21 Adjusted EBITDA is now expected to come in between $4.2-5.2 million, compared to the previous estimate of between $3.0-4.0 million."
Sandgaard advised that the company presently expects that FY/21 revenue will be between $135.0 and $150.0 million and noted those amounts are about 68-87% higher than the $80.1 million achieved in FY/20. In addition, the company now estimates that FY/21 adjusted EBITDA will come in between $15.0 and $25.0 million, versus the $13.7 million it earned in FY/20.
The firm stated that when it reports its complete Q2/21 earnings in late July, it will provide narrower and more precise data for FY/21 revenue and adjusted EBITDA expectations.
Sandgaard explained that "the company's prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain."
Zynex is a medical technology company based in Englewood, Colo. The firm manufactures and sells non-invasive electrotherapy medical devices designed for use in pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics. The company's efforts are centered around promoting its technology that can serve to eliminate patient addiction and other side effects caused from prescription opioids. The firm stated that "its proprietary NeuroMove device is designed to help recovery of stroke and spinal cord injury patients." Zynex indicated that it is also now working to develop a new blood volume monitor device designed for use in surgery centers and hospitals.
Zynex began the day with a market cap of around $529.3 million with approximately 34.85 million shares outstanding and a short interest of about 10.20%. ZYXI shares opened 4% higher today at $15.80 (+$0.61, +4.02%) over yesterday's $15.19 closing price. The stock has traded today between $15.79 to $16.519 per share and closed at $16.81 (+$1.62, +10.66%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
